In osteosarcoma, large variation is observed in the efficacy and toxicity of chemotherapeutic drugs among similarly treated patients. Treatment optimization using predictive factors or algorithms is of importance, because there has been a lack of improvement of treatment outcome and survival for decades. The outcome of cancer treatment is influenced by the genome, thus studying genetic variants involved in the efficacy and toxicity of the chemotherapeutic drugs used in the treatment of osteosarcoma could be an opportunity to optimize current treatments and improve our understanding of the individual's drug response in osteosarcoma patients. This review discusses the current insights in the pharmacogenetics of the treatment response of osteo...
Background: Standard treatment for osteosarcoma patients consists of a combination of cisplatin, adr...
The goal of cancer pharmacogenomics is to obtain benefit from personalized approaches of cancer trea...
Cellular responses to anti-cancer agents result from the interaction between drugs, cellular targets...
BACKGROUND: Osteosarcoma is the most common bone tumor in children and adolescents. Despite multiage...
Background : Osteosarcoma is the most common bone tumor in children and adolescents. Despite multiag...
Standard treatment for osteosarcoma patients consists of a combination of cisplatin, adriamycin, and...
Purpose: Overall survival in patients with osteosarcoma is only 60%. Poor response to chemotherapy i...
PURPOSE: Overall survival in patients with osteosarcoma is only 60%. Poor response to chemotherapy i...
<div><p><b><i>Introduction:</i></b> Drug-metabolizing enzymes (DMEs) biotransform several toxins and...
Objectives: Previous pharmacogenetics studies showed that genetic variants could be indicative of th...
Standard treatment for osteosarcoma patients consists of a combination of cisplatin, adriamyc...
This study aimed to identify associations between germline polymorphisms and risk of high-grade oste...
Pharmacogenomics and pharmacogenetics are emerging interdisciplinary areas recently defined, respect...
Osteosarcoma (OS) is the most common bone cancer in children and young adults. Most cases are high g...
Background: Standard treatment for osteosarcoma patients consists of a combination of cisplatin, adr...
The goal of cancer pharmacogenomics is to obtain benefit from personalized approaches of cancer trea...
Cellular responses to anti-cancer agents result from the interaction between drugs, cellular targets...
BACKGROUND: Osteosarcoma is the most common bone tumor in children and adolescents. Despite multiage...
Background : Osteosarcoma is the most common bone tumor in children and adolescents. Despite multiag...
Standard treatment for osteosarcoma patients consists of a combination of cisplatin, adriamycin, and...
Purpose: Overall survival in patients with osteosarcoma is only 60%. Poor response to chemotherapy i...
PURPOSE: Overall survival in patients with osteosarcoma is only 60%. Poor response to chemotherapy i...
<div><p><b><i>Introduction:</i></b> Drug-metabolizing enzymes (DMEs) biotransform several toxins and...
Objectives: Previous pharmacogenetics studies showed that genetic variants could be indicative of th...
Standard treatment for osteosarcoma patients consists of a combination of cisplatin, adriamyc...
This study aimed to identify associations between germline polymorphisms and risk of high-grade oste...
Pharmacogenomics and pharmacogenetics are emerging interdisciplinary areas recently defined, respect...
Osteosarcoma (OS) is the most common bone cancer in children and young adults. Most cases are high g...
Background: Standard treatment for osteosarcoma patients consists of a combination of cisplatin, adr...
The goal of cancer pharmacogenomics is to obtain benefit from personalized approaches of cancer trea...
Cellular responses to anti-cancer agents result from the interaction between drugs, cellular targets...